NGM Bio Announces Results From Phase 2 Study Of NGM282 In NASH Patients Demonstrating Clinically Significant Improvements In Liver Histology After 12 Weeks
Summary
The Phase 2 trial evaluated the efficacy, safety and tolerability of daily subcutaneous injections of 3 mg NGM282 over 12 weeks of treatment in patients with biopsy-confirmed NASH.These new histology data support the translation of those mechanisms into reversals of liver fibrosis in many patients, a clinically meaningful measure of disease outcomes," noted Alex DePaoli, M.D., Chief Medical Officer of NGM Bio.Key eligibility criteria were similar in both studies and included NAS ≥4 (with at least one point in each component of steatosis, lobular inflammation and hepatocellular ballooning), stage 1‐3 fibrosis and ≥8% LFC via MRI-PDFF.NGM Bio has generated robust preclinical and clinical evidence supporting the ability of NGM282 to resolve disease and reverse fibrosis in NASH patients.Related Links SOUTH SAN FRANCISCO, Calif., April 14, 2018 /PRNewswire/ -- NGM Bio, a leading biotech company developing a portfolio of clinical-stage product candidates that modulate novel or previously intractable targets implicated in metabolic and other serious diseases, today announced data from a Phase 2 study of its lead product candidate, NGM282, demonstrating clinically meaningful improvements in histological measures of disease in nonalcoholic steatohepatitis (NASH) patients at twelve weeks.